# US 2025/0051755 A1 · Platform for antibody discovery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0051755 A1
- Document ID: US20250051755A1
- Status: Published application
- Kind: A1
- Application number: 18/719,186
- Filed: 2022-12-19
- Published: 2025-02-13
- Earliest claimed: 2021-12-17
- Applicants: Dana-Farber Cancer Institute, Inc.
- Inventors: Barbel Schrofelbauer; Patrick Kimes; William Hahn
- Web page: https://patentgrep.com/patent/US20250051755A1

## CPC

- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C12N 15/1037: {Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display}
- C07K 16/2821: {against ICAM molecules, e.g. CD50, CD54, CD102}
- C07K 16/2839: {against the integrin superfamily}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C07K 16/32: against translation products of oncogenes
- C07K 16/40: against enzymes
- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- A61P 35/00: Antineoplastic agents
- C07K 16/005: {constructed by phage libraries}
- C07K 2317/10: characterized by their source of isolation or production
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/64: comprising a combination of variable region and constant region components
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G01N 2333/70578: NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention is directed to a high throughput platform for the simultaneous discovery of therapeutic antibodies and associated targets based on their phenotypic binding profiles, and monoclonal antibodies discovered therewith.

## Claims

### Claim at position 1

1-7. (canceled)

### Claim 2

(canceled)

### Claim 8

A method for the sequential selection and identification of an anti-cancer antibody and its target, the method comprising:
subjecting a phage display input library to affinity selection to produce an output library, wherein affinity selection comprises at least one panning step with a live cell sample positive for a biomarker and at least one panning step with a live cell sample negative for a biomarker;
selecting from the output library at least one antibody candidate based on sequence analysis, binding profiles, or both;
synthesizing, manufacturing, or isolating the selected antibody candidate;
optionally, validating the antibody candidate by flow cytometry; and
identifying the antibody candidate's target by mass spectrometry.

### Claim 9 (depends on 8)

The method of claim 8, further comprising obtaining the input library.

### Claim 10 (depends on 8)

The method of claim 8, further comprising producing the antibody candidate.

### Claim 11 (depends on 10)

The method of claim 10, wherein producing comprises cloning or synthesizing, reformatting, and expressing the antibody candidate.

### Claim 12 (depends on 8)

The method of claim 8, further comprising analyzing the output library to identify the antibody candidate.

### Claim 13

(canceled)

### Claim 14 (depends on 8)

The method of claim 8, wherein the input library comprises phage display, mammalian display, yeast display, bacterial display, ribosome display, or B-cells.

### Claim 15 (depends on 8)

The method of claim 8, wherein the input library comprises a naïve library, a synthetic library, a library generated after immunization of animals, or a combination thereof.

### Claim at position 11

16-19. (canceled)

### Claim 20 (depends on 8)

The method of claim 8, wherein the sample negative for a biomarker and/or the sample positive for a biomarker comprises a diseased state, a non-diseased state, and/or a combination thereof.

### Claim at position 13

21-25. (canceled)

### Claim 26 (depends on 12)

The method of claim 12, wherein analyzing comprises sequencing, computational pre-processing, and computational guided selection.

### Claim at position 15

27-29. (canceled)

### Claim 30 (depends on 11)

The method of claim 11, wherein the antibody candidate comprises a full-length antibody, a fusion protein, or an antibody fragment.

### Claim 31 (depends on 30)

The method of claim 30, wherein the antibody fragment comprises IgG, VH, Fab, scFv-Fc, diabody, scFv-CH3, scFab, scFv-zipper, scFv, or VHH.

### Claim 32 (depends on 8)

The method of claim 8, wherein validating comprises an immunoassay, a live cell binding assay, high throughput cell line multiplexing through fluorescent barcoding, plate based binding assays, high content analysis, or any combination thereof.

### Claim 33 (depends on 32)

The method of claim 32, wherein the immunoassay comprises flow cytometry, enzyme-linked immunosorbent assay (ELISA), plate based fluorescence binding assays, immunohistochemistry/fluorescent imaging, western blotting.

### Claim 34 (depends on 33)

The method of claim 33, wherein flow cytometry comprises fluorescence-activated cell sorting (FACS).

### Claim 35

(canceled)

### Claim 36 (depends on 8)

The method of claim 8, wherein the identifying comprises immunoprecipitation, affinity purification, protein microarray, or genetic approaches.

### Claim 37 (depends on 36)

The method of claim 36, wherein immunoprecipitation or affinity purification comprises:
linking an antibody with a label to produce a labeled antibody;
incubating the labeled antibody with a population of cells, wherein the labeled antibody binds to a target on the surface of the cells to produce an antibody-target conjugate;
isolating the antibody-target conjugate from the population of cells; and
identifying the target.

### Claim 38

(canceled)

### Claim 39 (depends on 37)

The method of claim 37, wherein the immunoprecipitation or affinity purification comprises antibody crosslinking.

### Claim at position 26

40-42. (canceled)

### Claim 43 (depends on 8)

The method of claim 8, wherein mass spectrometry analysis comprises LC-MS/MS, MALDI-TOF MS, ESI, or label free analysis based on MS signal intensity.

### Claim at position 28

44-45. (canceled)

### Claim 46 (depends on 8)

A method for generating a cancer cell surface map, the method comprising the method of claim 8, thereby producing the cancer cell surface map.

### Claim 47

A method for identifying a therapeutic target, comprising:
subjecting an input display library to affinity selection to produce an output library, wherein affinity selection comprises live cell panning;
analyzing the output library to identify one or more antibodies; and
identifying the target of the one or more antibodies, thereby identifying a therapeutic target and therapeutic antibody.

### Claim at position 31

48-49. (canceled)
